The Prognostic Value of Pretherapeutic Tetranectin and CA-125 in Patients with Relapse of Ovarian Cancer
- 1 December 2000
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 79 (3) , 416-419
- https://doi.org/10.1006/gyno.2000.5996
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Prognosis of 2,800 patients with epithelial ovarian cancer diagnosed during 1975-94 and treated at the Norwegian Radium HospitalActa Obstetricia et Gynecologica Scandinavica, 1998
- Pre-operative plasma tetranectin as a prognostic marker in ovarian cancer patientsScandinavian Journal of Clinical and Laboratory Investigation, 1993
- Tumor reduction surgery and long-term survival in advanced ovarian cancer: A DACOVA studyGynecologic Oncology, 1990
- Predictive value of CA 125 during early chemotherapy of advanced ovarian cancerGynecologic Oncology, 1990
- Ovarian cancer: The prognostic value of the serum half-life of CA125 during induction chemotherapyGynecologic Oncology, 1988
- Prognostic factors in advanced ovarian carcinoma.Journal of Clinical Oncology, 1986
- Purification and characterization of a novel, oligomeric, plasminogen kringle 4 binding protein from human plasma: tetranectinEuropean Journal of Biochemistry, 1986
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983
- The Fibrinolytic SystemAnnals of Surgery, 1979
- Fibrin Degradation Products and Ovarian TumoursBMJ, 1971